Loading
A phase 2 trial of Gemcitabine, Oxaliplatin and TQB2825 in non-Hodgkin lymphoma, run by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., now recruiting.
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma is a phase 2 interventional study registered as NCT06854445 by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., with 55 participants planned, started 2025-03-12 and due to reach its primary completion in 2025-10. Interventions recorded: TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Gemcitabine and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Oxaliplatin and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Oxaliplatin, Gemcitabine and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/